BioAdaptives swung to net income of US$150,090 in the quarter ended June 30, 2026, from a net loss of US$157,914.
Revenue more than doubled to US$4,249 from a year earlier, while operating expenses fell 28.14% to US$201,416.
Other income rose to US$347,266, reflecting a US$446,739 change in the fair value of derivative liabilities.
Cash totaled US$29,221 at June 30, 2026, with a working-capital deficit of US$1.77 million.
Business updates
Business updates included May test marketing for MyndSystem, slow early marketing for Xcellara, and limited PawPa Regen sales via its website and Amazon.
BDPT•
